Przeciwciała monoklonalne (Q26012): Difference between revisions

@@ Property / Version @@
-Tissaia de Vries
@@ Property / Version: Tissaia de Vries / rank @@
-Normal rank
@@ Property / National Library Identifier @@
+a0000002148927
@@ Property / National Library Identifier: a0000002148927 / rank @@
+Normal rank
@@ Property / Related Subject @@
+Antygeny i przeciwciała
@@ Property / Related Subject: Antygeny i przeciwciała / rank @@
+Normal rank
@@ Property / Related Subject @@
+Leki ukierunkowane molekularnie
@@ Property / Related Subject: Leki ukierunkowane molekularnie / rank @@
+Normal rank
@@ Property / Related Subject @@
+Immunoterapia
@@ Property / Related Subject: Immunoterapia / rank @@
+Normal rank
@@ Property / Related Subject @@
+Leczenie onkologiczne
@@ Property / Related Subject: Leczenie onkologiczne / rank @@
+Normal rank
@@ Property / Related Subject @@
+Adalimumab
@@ Property / Related Subject: Adalimumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Adukanumab
@@ Property / Related Subject: Adukanumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Alemtuzumab
@@ Property / Related Subject: Alemtuzumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Atezolizumab
@@ Property / Related Subject: Atezolizumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Avelumab
@@ Property / Related Subject: Avelumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Benralizumab
@@ Property / Related Subject: Benralizumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Bewacyzumab
@@ Property / Related Subject: Bewacyzumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Blinatumomab
@@ Property / Related Subject: Blinatumomab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Denosumab
@@ Property / Related Subject: Denosumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Golimumab
@@ Property / Related Subject: Golimumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Guselkumab
@@ Property / Related Subject: Guselkumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Iksekizumab
@@ Property / Related Subject: Iksekizumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Infliksymab
@@ Property / Related Subject: Infliksymab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Lokivetmab
@@ Property / Related Subject: Lokivetmab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Mepolizumab
@@ Property / Related Subject: Mepolizumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Natalizumab
@@ Property / Related Subject: Natalizumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Niwolumab
@@ Property / Related Subject: Niwolumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Omalizumab
@@ Property / Related Subject: Omalizumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Ranibizumab
@@ Property / Related Subject: Ranibizumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Romosozumab
@@ Property / Related Subject: Romosozumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Rytuksymab
@@ Property / Related Subject: Rytuksymab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Secukinumab
@@ Property / Related Subject: Secukinumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Tocilizumab
@@ Property / Related Subject: Tocilizumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Trastuzumab
@@ Property / Related Subject: Trastuzumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Ustekinumab
@@ Property / Related Subject: Ustekinumab / rank @@
+Normal rank
@@ Property / Related Subject @@
+Vedolizumab
@@ Property / Related Subject: Vedolizumab / rank @@
+Normal rank
@@ Property / Type @@
+Unknown
@@ Property / Type: Unknown / rank @@
+Normal rank
@@ Property / Version @@
+P19606T22242
@@ Property / Version: P19606T22242 / rank @@
+Normal rank